コンテンツへスキップ
Merck

F0891

Sigma-Aldrich

Flumethasone pivalate

別名:

6α,9-Difluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 21-(2,2-dimethylpropionate), Flumetasone 21-pivalate, NSC 107680

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C27H36F2O6
CAS番号:
分子量:
494.57
EC Number:
MDL番号:
UNSPSCコード:
51101500
PubChem Substance ID:
NACRES:
NA.85

フォーム

solid

光学活性

[α]25/D 71.0 to 82.0°, c = 1 in dioxane

溶解性

dioxane: 4.0 mL, clear, colorless to very faintly yellow (50 mg + 4.0 mL dioxane)

作用機序

cell membrane | interferes

SMILES記法

[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])C[C@H](F)C4=CC(=O)C=C[C@]34C

InChI

1S/C27H36F2O6/c1-14-9-16-17-11-19(28)18-10-15(30)7-8-24(18,5)26(17,29)20(31)12-25(16,6)27(14,34)21(32)13-35-22(33)23(2,3)4/h7-8,10,14,16-17,19-20,31,34H,9,11-13H2,1-6H3/t14-,16+,17+,19+,20+,24+,25+,26+,27+/m1/s1

InChI Key

JWRMHDSINXPDHB-OJAGFMMFSA-N

遺伝子情報

human ... NR3C1(2908)

類似した製品をお探しですか? 訪問 製品比較ガイド

アプリケーション

Flumethasone pivalate is a topical difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. A prompt decrease in inflammation, exudation and itching is experienced after application. It is used to study adrenocortical suppression, plasma transcortin binding, and cutaneous atrophy and telangiectasia.

生物化学的/生理学的作用

Flumethasone pivalate is a glucocorticoid receptor agonist used in studies on plasma transcortin binding. It binds to the nucleus causing a variety of genetic activations and repressions. The anti-inflammatory action of flumethasone is thought to involve lipocortins and phospholipase A2 inhibitory proteins, which results in the inhibition of arachidonic acid and the control of prostaglandin and leukotriene biosynthesis. Flumethasone suppresses the immune system due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.

ピクトグラム

Health hazard

シグナルワード

Warning

危険有害性情報

危険有害性の分類

Carc. 2

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable

個人用保護具 (PPE)

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

F0891-500MG:
F0891-100MG:
F0891-VAR:
F0891-50MG:
F0891-BULK:


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

[Double-blind comparison of a betamethasone dipropionate-iodochloroxyquinoline combination and a flumethasone pivalate-iodochloroxyquinoline combination in the therapy of steroid-sensitive dermatoses with superinfection].
M Mosca et al.
Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 121(1), XI-XIV (1986-01-01)
Contact allergy to EDTA in a topical corticosteroid preparation.
A C de Groot
Contact dermatitis, 15(4), 250-252 (1986-10-01)
V Wienert et al.
Archives of dermatological research, 271(1), 19-27 (1981-01-01)
Test results are reported of the effect of salicylic acid on the vasoconstrictive effect of flumethasone pivalate. In specific, the depigmentation of the skin (identical with increase in lightness of the skin) following topical application of flumethasone pivalate was investigated
F Scaglione et al.
Drugs under experimental and clinical research, 11(8), 523-526 (1985-01-01)
The combination flumethasone pivalate + iodochlorohydroxychinoline drops was used in 40 patients, 24 males and 16 females, mean age 42.6 years, suffering from infectious enanthema (35%), periodontitis (30%), aphthous stomatitis (25%) and abscess due to prosthesis (10%). After application of
M Shohat et al.
Clinical pediatrics, 25(4), 209-212 (1986-04-01)
Fifteen infants with seborrheic dermatitis were treated with topical glucocorticosteroids (flumethasone pivalate 0.02%). Early morning plasma cortisol levels were determined prior to treatment, during the 10-day treatment period, and 2 days after its termination. The mean plasma cortisol level prior

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)